242 related articles for article (PubMed ID: 36827371)
1. Xeno interactions between MHC-I proteins and molecular chaperones enable ligand exchange on a broad repertoire of HLA allotypes.
Sun Y; Papadaki GF; Devlin CA; Danon JN; Young MC; Winters TJ; Burslem GM; Procko E; Sgourakis NG
Sci Adv; 2023 Feb; 9(8):eade7151. PubMed ID: 36827371
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of chaperone interactions on MHC-I for folding and antigen repertoire selection.
McShan AC; Devlin CA; Overall SA; Park J; Toor JS; Moschidi D; Flores-Solis D; Choi H; Tripathi S; Procko E; Sgourakis NG
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25602-25613. PubMed ID: 31796585
[TBL] [Abstract][Full Text] [Related]
3. Distinct Polymorphisms in HLA Class I Molecules Govern Their Susceptibility to Peptide Editing by TAPBPR.
Ilca FT; Drexhage LZ; Brewin G; Peacock S; Boyle LH
Cell Rep; 2019 Nov; 29(6):1621-1632.e3. PubMed ID: 31693900
[TBL] [Abstract][Full Text] [Related]
4. A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor.
Sagert L; Hennig F; Thomas C; Tampé R
Elife; 2020 Mar; 9():. PubMed ID: 32167472
[TBL] [Abstract][Full Text] [Related]
5. TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap.
McShan AC; Devlin CA; Morozov GI; Overall SA; Moschidi D; Akella N; Procko E; Sgourakis NG
Nat Commun; 2021 May; 12(1):3174. PubMed ID: 34039964
[TBL] [Abstract][Full Text] [Related]
6. TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules.
McShan AC; Devlin CA; Papadaki GF; Sun Y; Green AI; Morozov GI; Burslem GM; Procko E; Sgourakis NG
Nat Chem Biol; 2022 Aug; 18(8):859-868. PubMed ID: 35725941
[TBL] [Abstract][Full Text] [Related]
7. TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst.
Hermann C; van Hateren A; Trautwein N; Neerincx A; Duriez PJ; Stevanović S; Trowsdale J; Deane JE; Elliott T; Boyle LH
Elife; 2015 Oct; 4():. PubMed ID: 26439010
[TBL] [Abstract][Full Text] [Related]
8. Reanalysis of Immunopeptidomics Datasets Provides Mechanistic Insight into TAPBPR-Mediated Peptide Editing on HLA-A, -B and -C Molecules.
Altenburg AF; Morley JL; Bauer J; Walz JS; Boyle LH
Wellcome Open Res; 2024; 9():113. PubMed ID: 38800518
[TBL] [Abstract][Full Text] [Related]
9. Peptide exchange on MHC-I by TAPBPR is driven by a negative allostery release cycle.
McShan AC; Natarajan K; Kumirov VK; Flores-Solis D; Jiang J; Badstübner M; Toor JS; Bagshaw CR; Kovrigin EL; Margulies DH; Sgourakis NG
Nat Chem Biol; 2018 Aug; 14(8):811-820. PubMed ID: 29988068
[TBL] [Abstract][Full Text] [Related]
10. The role of MHC I protein dynamics in tapasin and TAPBPR-assisted immunopeptidome editing.
van Hateren A; Elliott T
Curr Opin Immunol; 2021 Jun; 70():138-143. PubMed ID: 34265495
[TBL] [Abstract][Full Text] [Related]
11. A Chicken Tapasin ortholog can chaperone empty HLA-B∗37:01 molecules independent of other peptide-loading components.
Papadaki GF; Woodward CH; Young MC; Winters TJ; Burslem GM; Sgourakis NG
J Biol Chem; 2023 Oct; 299(10):105136. PubMed ID: 37543367
[TBL] [Abstract][Full Text] [Related]
12. TAPBPR mediates peptide dissociation from MHC class I using a leucine lever.
Ilca FT; Neerincx A; Hermann C; Marcu A; Stevanović S; Deane JE; Boyle LH
Elife; 2018 Nov; 7():. PubMed ID: 30484775
[TBL] [Abstract][Full Text] [Related]
13. Production of soluble pMHC-I molecules in mammalian cells using the molecular chaperone TAPBPR.
O'Rourke SM; Morozov GI; Roberts JT; Barb AW; Sgourakis NG
Protein Eng Des Sel; 2019 Dec; 32(12):525-532. PubMed ID: 32725167
[TBL] [Abstract][Full Text] [Related]
14. The ER folding sensor UGGT1 acts on TAPBPR-chaperoned peptide-free MHC I.
Sagert L; Winter C; Ruppert I; Zehetmaier M; Thomas C; Tampé R
Elife; 2023 Jun; 12():. PubMed ID: 37345806
[TBL] [Abstract][Full Text] [Related]
15. Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway.
Natarajan K; Jiang J; Margulies DH
Crit Rev Biochem Mol Biol; 2019 Apr; 54(2):164-173. PubMed ID: 31084439
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR.
Xu H; Song K; Da LT
Phys Chem Chem Phys; 2022 May; 24(20):12397-12409. PubMed ID: 35575131
[TBL] [Abstract][Full Text] [Related]
17. Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation.
Neerincx A; Boyle LH
Mol Immunol; 2019 Sep; 113():58-66. PubMed ID: 30077416
[TBL] [Abstract][Full Text] [Related]
18. Visualising tapasin- and TAPBPR-assisted editing of major histocompatibility complex class-I immunopeptidomes.
van Hateren A; Elliott T
Curr Opin Immunol; 2023 Aug; 83():102340. PubMed ID: 37245412
[TBL] [Abstract][Full Text] [Related]
19. The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.
Ilca FT; Boyle LH
Mol Immunol; 2021 Nov; 139():168-176. PubMed ID: 34543843
[TBL] [Abstract][Full Text] [Related]
20. Structure of the TAPBPR-MHC I complex defines the mechanism of peptide loading and editing.
Thomas C; Tampé R
Science; 2017 Nov; 358(6366):1060-1064. PubMed ID: 29025996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
